Our Entrepreneur Partners are core to our investment strategy, providing deep domain expertise, capabilities across the entire drug development process and experience navigating the complex regulatory landscape. Our entrepreneurs and investment professionals bring unique expertise to inform every investment decision – private or public, across all phases of development.

MPM BioImpact combines the 30+ year track record of the MPM CAPITAL^® services and offerings in biotech venture capital with BioImpact’s dedication to impact and 10+ years of experience in public investing. Together, we manage over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund.

The BIOIMPACT FUND™ investment approach pioneered by MPM BioImpact features private and public equity funds that invest in companies which aim to transform the lives and outcomes of patients suffering from disease.

The ONCOLOGY IMPACT FUND™ (OIF) investment approach, part of MPM BioImpact’s investment philosophy and family of funds, is one of the world’s largest biotech impact investing strategies. The OIF approach creates and invests in public and private companies developing innovative treatments for cancer and other diseases with significant unmet medical needs. Beyond oncology, OIF investments support cutting-edge therapeutic technologies, including cell, gene and RNA therapies. MPM BioImpact has partnered with UBS Global Wealth Management across both OIF I and OIF II.

We are proud to be committed to the Global Standards for managing these impact investments.